The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Kepler Capital analyst David Evans maintained a Hold rating on Novo Nordisk (0QIU – Research Report) on February 5 and set a price target of ...
A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. REUTERS/Tom Little//File Photo · Reuters / Reuters The company ...
JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...
On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as good as those in the trials cited above, however, the speed at which they ...
Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.